ArticleFrontiers in cell and developmental biology2022
Hypoxia-immune-related microenvironment prognostic signature for osteosarcoma.
Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 17 citations in OpenAlex.
- A 'three-axis synergy' immunotherapeutic strategy for malignant bone tumors based on natural bioactives and bioactive materials.Bioactive materials · 2026Review
- Article
- Unaltered NKG2D-CAR T cell function under hypoxia in osteosarcoma in vitro.Cancer immunology, immunotherapy : CII · 2026Article
- Metabolic profiling of the TME uncovers the contrasting impacts of CKMT2 and PDE2A in CRC progression and therapeutic response.Frontiers in pharmacology · 2026Article
- Integrative biomarker and drug target discovery in osteosarcoma: traditional experimental approaches and AI-enabled insights.Frontiers in pharmacology · 2026Review
- Creatine Kinase Blockade Disrupts Energy Metabolism and Redox Homeostasis to Suppress Osteosarcoma Progression.International journal of molecular sciences · 2025Article
- Exploring the Tumor Microenvironment in Osteosarcoma: Driver of Resistance and Progression.Cancers · 2025Review
- Osteopontin derived from hypoxia-induced M2 macrophages promotes osteosarcoma progression through modulation of EGR3/ISG15 signaling and RIG-I expression.Journal of translational medicine · 2025Article
- The neutrophil extracellular trap-related gene FPR1 (formyl peptide receptor 1) as a potential prognostic and therapeutic target in osteosarcoma.BMC musculoskeletal disorders · 2025Article
- Construction and validation of a prognostic signature using WGCNA-identified key genes in osteosarcoma for treatment evaluation.Translational cancer research · 2025Article
- Deubiquitinase Genes as Prognostic Biomarkers in Osteosarcoma: Insights From Single-Cell Sequencing and Machine Learning-Based Prognostic Modeling.International journal of genomics · 2025Article
- Mitochondrial Creatine Kinase 2 (Ckmt2) as a Plasma-Based Biomarker for Evaluating Reperfusion Injury in Acute Myocardial Infarction.Biomedicines · 2024Article
- Creatine kinase mitochondrial 2 promotes the growth and progression of colorectal cancerPeerJ · 2024Article
- A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma.Frontiers in immunology · 2024Article
- Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.Cancers · 2023Review
- Toward quantification of hypoxia using fluorinated EuProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Targeting Ferroptosis in Bone-Related Diseases: Facts and Perspectives.Journal of inflammation research · 2023Review
- Construction of a 5-gene prognostic signature based on oxidative stress related genes for predicting prognosis in osteosarcoma.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.